|
MechanismHIF-PHs inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date29 Jun 2020 |
|
MechanismH3 receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date31 Mar 2016 |
A double-blind, placebo-controlled, clinical pharmacology study to investigate the safety, tolerability and pharmacokinetics of single and multiple doses of MT-5199 in healthy male Korean subjects
100 Clinical Results associated with Mitsubishi Tanabe Pharma Korea Co., Ltd.
0 Patents (Medical) associated with Mitsubishi Tanabe Pharma Korea Co., Ltd.
100 Deals associated with Mitsubishi Tanabe Pharma Korea Co., Ltd.
100 Translational Medicine associated with Mitsubishi Tanabe Pharma Korea Co., Ltd.